Literature DB >> 30645730

MicroRNA-mediated redox regulation modulates therapy resistance in cancer cells: clinical perspectives.

Safieh Ebrahimi1,2, Seyed Isaac Hashemy3,4.   

Abstract

BACKGROUND: Chemotherapy and radiation therapy are the most common types of cancer therapy. The development of chemo/radio-resistance remains, however, a major obstacle. Altered redox balances are among of the main factors mediating therapy resistance. Therefore, redox regulatory strategies are urgently needed to overcome this problem. Recently, microRNAs have been found to act as major redox regulatory factors affecting chemo/radio-resistance. MicroRNAs play critical roles in regulating therapeutic resistance through the regulation of antioxidant enzymes, redox-sensitive signaling pathways, cancer stem cells, DNA repair mechanisms and autophagy.
CONCLUSIONS: Here, we summarize current knowledge on microRNA-mediated redox regulatory mechanisms underlying chemo/radio-resistance. This knowledge may form a basis for a better clinical management of cancer patients.

Entities:  

Keywords:  Cancer; Chemotherapy; MicroRNA; Radiotherapy; Redox regulation; Resistance

Mesh:

Substances:

Year:  2019        PMID: 30645730     DOI: 10.1007/s13402-018-00421-z

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  11 in total

Review 1.  The emerging role of noncoding RNAs in colorectal cancer chemoresistance.

Authors:  Ling Wei; Xingwu Wang; Liyan Lv; Yan Zheng; Nasha Zhang; Ming Yang
Journal:  Cell Oncol (Dordr)       Date:  2019-07-29       Impact factor: 6.730

2.  lncRNA TUG1 promotes the development of oral squamous cell carcinoma by regulating the MAPK signaling pathway by sponging miR-593-3p.

Authors:  Lei Jiang; Bing Zhou; Dongjie Fu; Bo Cheng
Journal:  Cell Cycle       Date:  2022-05-23       Impact factor: 5.173

Review 3.  HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer.

Authors:  Kim Jun Cheng; Mohammed Abdullah Alshawsh; Elsa Haniffah Mejia Mohamed; Surendran Thavagnanam; Ajantha Sinniah; Zaridatul Aini Ibrahim
Journal:  Cell Oncol (Dordr)       Date:  2019-11-01       Impact factor: 6.730

4.  WNT1, a target of miR-34a, promotes cervical squamous cell carcinoma proliferation and invasion by induction of an E-P cadherin switch via the WNT/β-catenin pathway.

Authors:  Baohua Li; Xuedong Guo; Na Li; Qin Chen; Junhua Shen; Xiaoxiu Huang; Genping Huang; Fenfen Wang
Journal:  Cell Oncol (Dordr)       Date:  2020-04-16       Impact factor: 6.730

5.  LncRNA GAS5 Suppressed Proliferation and Promoted Apoptosis in Laryngeal Squamous Cell Carcinoma by Targeting MiR-26a-5p and Modifying ULK2.

Authors:  Jian Wang; Yiming Zhu; Song Ni; Shaoyan Liu
Journal:  Cancer Manag Res       Date:  2021-01-29       Impact factor: 3.989

6.  The Effect of SP/NK1R on the Expression and Activity of Catalase and Superoxide Dismutase in Glioblastoma Cancer Cells.

Authors:  Faranak Korfi; Hossein Javid; Reza Assaran Darban; Seyed Isaac Hashemy
Journal:  Biochem Res Int       Date:  2021-04-21

7.  Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-κB Signal Transduction Pathways in Colon Cancer Cells.

Authors:  Atefeh Ghahremanloo; Hossein Javid; Amir R Afshari; Seyed Isaac Hashemy
Journal:  Biomed Res Int       Date:  2021-08-02       Impact factor: 3.411

8.  Downregulated Expression of miRNA-130a-5p Aggravates Hepatoma Progression via Targeting PTP4A2.

Authors:  Longqing Shi; Fengbo Wang; Yue Zhang; Yue Yang; Zheng Qu; Donglin Sun
Journal:  Comput Math Methods Med       Date:  2021-12-28       Impact factor: 2.238

9.  MicroRNA (MiR)-301a-3p regulates the proliferation of esophageal squamous cells via targeting PTEN.

Authors:  Nan Zhang; Jun Feng Liu
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

Review 10.  Noncoding RNAs in gastric cancer: implications for drug resistance.

Authors:  Ling Wei; Jujie Sun; Nasha Zhang; Yan Zheng; Xingwu Wang; Liyan Lv; Jiandong Liu; Yeyang Xu; Yue Shen; Ming Yang
Journal:  Mol Cancer       Date:  2020-03-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.